Oligonucleotides News and Research

RSS

Oligonucleotides are short sequences of nucleotides (RNA or DNA), typically with twenty or fewer bases. Automated synthesizers allow the synthesis of oligonucleotides up to 160 to 200 bases.

New consensus guidelines for toxicity testing of oligonucleotide-based therapeutics

Oligonucleotide-based therapeutics present unique challenges when it comes to testing their potential to cause reproductive and developmental harm. New consensus guidelines for toxicity testing that take into consideration the combined chemical and biological characteristics of these novel biopharmaceuticals are presented in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers.

31 Oct 2014

Identifying infections rapidly: an interview with Dr. David J. Ecker

Current methods for diagnosing infectious diseases are based on the 150-year-old culture method, where physicians collect a sample of a patient’s tissue, such as blood, mucus or urine, and transfer it onto media bottle to allow the pathogens to grow.

From Abbott Diagnostics 20 Oct 2014

TSRI scientists awarded DARPA grant to build artificial immune system

Scientists from both campuses of The Scripps Research Institute have been awarded a total of $7.9 million from the Defense Advanced Research Projects Agency of the U.S. Department of Defense.

25 Sep 2014

Phase IIa clinical trial data of ATL1102 in MS patients published in journal Neurology

Antisense Therapeutics is pleased to report the publication of previously generated Phase IIa clinical trial data on ATL1102 in the medical journal Neurology.

22 Sep 2014

Regulus begins ATHENA study to monitor changes in renal function in Alport syndrome patients

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today it has initiated its ATHENA natural history of disease study in patients with Alport syndrome, a life-threatening genetic kidney disease with no approved therapy.

19 Sep 2014

MU researchers make new breakthrough in spinal muscular atrophy drug

According to recent studies, approximately one out of every 40 individuals in the United States is a carrier of the gene responsible for spinal muscular atrophy (SMA), a neurodegenerative disease that causes muscles to weaken over time.

16 Sep 2014

Researchers find method to repair gene mutation causing autoimmune deficiency disease

Researchers at Karolinska Institutet in Sweden have found a method to repair the gene mutation causing agammaglobulinemia, an autoimmune deficiency disease that almost exclusively affects boys and in which the body lacks the ability to produce immunoglobulins (gamma globulin).

14 Aug 2014

Idera collaborates with TMA to advance new potential treatment approach for myositis

Idera Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing nucleic acid therapeutics for patients with cancer and rare diseases, and The Myositis Association (TMA), the only nonprofit organization dedicated to solely serving all patients with inflammatory myopathies, today announced a collaboration to advance a new potential treatment approach for polymyositis and dermatomyositis known as Toll-like receptor (TLR) antagonism.

7 Aug 2014

Splice-switching oligonucleotide drugs alter editing of gene transcript

In splice-switching, an innovative therapeutic approach, targeted oligonucleotide drugs alter the editing of a gene transcript to produce the desired form of a protein.

18 Jul 2014

Study of cancer radiation therapy shows that DNA building blocks are susceptible to fragmentation

A new study relevant for cancer radiation therapy shows that DNA building blocks are susceptible to fragmentation. Scientists now have a better understanding of how short DNA strands decompose in microseconds

16 Jul 2014

High-resolution, high-throughput pre-implantation genetic screening microarray launched by OGT

Oxford Gene Technology (OGT), The Molecular Genetics Company, has announced the launch of a new high-resolution, high-throughput pre-implantation genetic screening (PGS) microarray aimed at improving embryo screening for in vitro fertilisation (IVF). The CytoSure™ Embryo Screen Array offers eight arrays of 60,000 spots for high-resolution genome-wide aneuploidy and copy number detection in pre-implantation embryos.

From Oxford Gene Technology 8 Jul 2014

Celsion acquires all assets of EGEN

Celsion Corporation, an oncology drug development company, today announced the completion of the acquisition by Celsion of substantially all of the assets of EGEN, Inc., a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases.

21 Jun 2014

Celsion signs definitive asset purchase agreement to acquire EGEN

Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas™ for delivery of DNA and mRNA, TheraSilence™ for delivery of RNA, and RAST™ for Cell Enabled Expression and Secretion of RNA.

10 Jun 2014

Twist Bioscience raises $26M in Series B financing, receives $5.1M DARPA contract

Twist Bioscience today announced that it raised $26 million in a Series B financing to commercialize the company's semiconductor-based synthetic gene manufacturing process.

27 May 2014

New mouse study indicates that mutant protein in muscle cells is responsible for SBMA

Sometimes known as Kennedy's disease, spinal and bulbar muscular atrophy (SBMA) is a rare inherited neuromuscular disorder characterized by slowly progressive muscle weakness and atrophy.

17 Apr 2014

Blood sample could diagnose many types of solid cancers

A blood sample could one day be enough to diagnose many types of solid cancers, or to monitor the amount of cancer in a patient's body and responses to treatment. Previous versions of the approach, which relies on monitoring levels of tumor DNA circulating in the blood, have required cumbersome and time-consuming steps to customize it to each patient or have not been sufficiently sensitive.

7 Apr 2014

ANP reports positive results from chronic toxicity study of ATL1102 in multiple sclerosis

Antisense Therapeutics Limited is pleased to advise that results from a chronic toxicity study in monkeys indicate that ATL1102, an antisense oligonucleotide currently under development for the treatment of multiple sclerosis (MS), was well-tolerated when given subcutaneously for a 6-month dosing period at the 2 dose levels tested (1.5 and 3mg/kg/dose).

2 Apr 2014

Idera Pharmaceuticals reports positive top-line results from Phase 2 trial of IMO-8400

Idera Pharmaceuticals, Inc. today announced positive top-line data from its randomized, double-blind, placebo controlled Phase 2 trial of IMO-8400 in 32 patients with moderate-to-severe plaque psoriasis.

28 Mar 2014

Chemical engineers design way to manufacture peptides in mere hours

Small protein fragments, also called peptides, are promising as drugs because they can be designed for very specific functions inside living cells. Insulin and the HIV drug Fuzeon are some of the earliest successful examples, and peptide drugs are expected to become a $25 billion market by 2018.

19 Mar 2014

OPKO Health consolidated revenues increase about 30% to $20.7 million in Q4 2013

OPKO Health, Inc., a multi-national biopharmaceutical and diagnostics company, today reported operating and financial results for its 2013 fourth quarter and full year ended December 31, 2013.

4 Mar 2014

Oligonucleotides News and Research

Further Reading

New consensus guidelines for toxicity testing of oligonucleotide-based therapeutics

Identifying infections rapidly: an interview with Dr. David J. Ecker

TSRI scientists awarded DARPA grant to build artificial immune system

Phase IIa clinical trial data of ATL1102 in MS patients published in journal Neurology

Regulus begins ATHENA study to monitor changes in renal function in Alport syndrome patients

MU researchers make new breakthrough in spinal muscular atrophy drug

Researchers find method to repair gene mutation causing autoimmune deficiency disease

Idera collaborates with TMA to advance new potential treatment approach for myositis

Splice-switching oligonucleotide drugs alter editing of gene transcript

Study of cancer radiation therapy shows that DNA building blocks are susceptible to fragmentation

High-resolution, high-throughput pre-implantation genetic screening microarray launched by OGT

Celsion acquires all assets of EGEN

Celsion signs definitive asset purchase agreement to acquire EGEN

Twist Bioscience raises $26M in Series B financing, receives $5.1M DARPA contract

New mouse study indicates that mutant protein in muscle cells is responsible for SBMA

Blood sample could diagnose many types of solid cancers

ANP reports positive results from chronic toxicity study of ATL1102 in multiple sclerosis

Idera Pharmaceuticals reports positive top-line results from Phase 2 trial of IMO-8400

Chemical engineers design way to manufacture peptides in mere hours

OPKO Health consolidated revenues increase about 30% to $20.7 million in Q4 2013

Biochemistry eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics